From: Immunohistochemical evaluation of ROCK activation in invasive breast cancer
 | Hazard ratio (95 % CI) | P |
---|---|---|
Model 1 | ||
Age (year) | 1.019 (1.001, 1.037) | 0.044 |
Grade | ||
 1 | 1 |  |
 2 | 1.935 (0.258, 14.529) | 0.521 |
 3 | 1.062 (0.132, 8.565) | 0.955 |
Stage | ||
 I | 1 |  |
 II | 1.811 (0.673, 4.875) | 0.240 |
 III | 6.144 (2.264, 16.677) | < 0.001 |
 IV | 58.450 (9.985, 342.165) | < 0.001 |
ER+ | 0.403 (0.169, 0.963) | 0.041 |
PR+ | 1.768 (0.734, 4.262) | 0.204 |
HER2+ | 1.302 (0.688, 2.463) | 0.418 |
Nuclear pROCKII ≥ 30 % | 1.414 (0.715, 2.794) | 0.319 |
Model 2 | ||
Age (year) | 1.019 (1.000, 1.039) | 0.050 |
Grade | ||
 1 | 1 |  |
 2 | 3.244 (0.442, 23.801) | 0.247 |
 3 | 2.299 (0.297, 17.784) | 0.425 |
ER+ | 0.563 (0.241, 1.316) | 0.185 |
PR+ | 1.253 (0.532, 2.952) | 0.605 |
HER2+ | 1.315 (0.713, 2.425) | 0.381 |
Nuclear pROCKII ≥ 30 % | 2.116 (1.152, 3.888) | 0.016 |